5 research outputs found
Bioactive compounds by microalgae and potentials for the management of some human disease conditions
Recommended from our members
Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases
Diseases affecting the anterior segment of the eye are the primary causes of vision impairment and blindness globally. Drug administration through the topical ocular route is widely accepted because of its user/patient friendliness - ease of administration and convenience. However, it remains a significant challenge to efficiently deliver drugs to the eye through this route because of various structural and physiological constraints that restrict the distribution of therapeutic molecules into the ocular tissues. The bioavailability of topically applied ocular medications such as eye drops is typically less than 5%. Developing novel delivery systems to increase the retention time on the ocular surfaces and permeation through the cornea is one of the approaches adopted to boost the bioavailability of topically administered medications. Drug delivery systems based on nanotechnology such as micelles, nanosuspensions, nanoparticles, nanoemulsions, liposomes, dendrimers, niosomes, cubosomes and nanowafers have been investigated as effective alternatives to conventional ocular delivery systems in treating diseases of the anterior segment of the eye. This review discussed different nanotechnology-based delivery systems that are currently investigated for treating and managing diseases affecting the anterior ocular tissues. We also looked at the challenges in translating these systems into clinical use and the prospects of nanocarriers as a vehicle for the delivery of phytoactive compounds to the anterior segment of the eye
Neuropharmacological evaluation of the methanol leaf extract of Phyllanthus muellerianus (Kuntze) Exell and its ethyl acetate fraction in mice
Purpose: To investigate the neuropharmacological effects of the methanol leaf extract (ME) and fractions of Phyllanthus muellerianus (PM) (Phyllanthaceae) (Kuntze) Exell (PM) in mice.
Methods: Acute toxicity was carried out on the extract using standard protocol. ME was fractionated into hexane (HF), ethyl acetate (EF), and methanol (MF) fractions. Pentylenetetrazol (PTZ)-induced seizure, open field (OF) and motor coordination (rotarod) tests were models employed. Mice allotted into fourteen groups of six animals each were treated orally with 100, 200, or 400 mg/kg of the extract and fractions in pentylene tetrazole (PTZ) seizure model. Seizure was induced with intraperitoneal (ip) injection of 70 mg/kg of PTZ. The positive and negative controls employed were phenobarbitone (35 mg/kg) and 5 ml/kg of 7 % Tween 80, respectively. In the OF and motor coordination tests, six groups of six mice were treated orally with ME and EF at 200 and 400 mg/kg doses. Control groups received either 5 ml/kg of 7% Tween 80 or diazepam (1 mg/kg ip) as negative and positive controls respectively
Results: In the PTZ model, only EF abolished seizures completely (p<0.05), when compared with the negative control, producing 100% protection, even better than the phenobarbitone which gave 83.3% protection. In the OFT, in comparison with the control, ME at 400 mg/kg (p < 0.05) decreased both the number of line crossing and the number of assisted rearing similar to that produced by diazepam. EF increased both the locomotor and exploratory activities significantly (p < 0.05) in mice. ME at 400 mg/kg significantly (p < 0.05) evoked reduction in the time of fall of mice from the rotarod when compared to the control in the same way as diazepam while EF did not elicit any appreciable differences.
Conclusion: ME has anticonvulsant, sedative, and anxiolytic activities, while EF possesses anticonvulsant and anxiolytic activities devoid of sedative and cognitive impairment. The observed anticonvulsant effect was better than that produced by phenobarbitone. Thus, it may be a good lead for developing antiepileptic and other central nervous system active agents